This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
UK drugmaker says Emma Walmsley is underpaid compared with global competitors
Guidance on the details of the classification of variations requiring assessment...
Infographic - Orphan Medicines in the EU
Why one health care investor buys “zombie” biotechs to shut them down.
Human medicines European public assessment report (EPAR): Soliris, eculizumab, D...
Biotech venture capital is on the precipice of a generational shift. At least, t...
Universities accept less than their actual overhead costs from private sources b...
A progressive approach to drug approval would balance the reality of drug safety...
The federal government’s work on long Covid has been fitful and disappointing. N...
Human medicines European public assessment report (EPAR): Spinraza, nusinersen, ...
Human medicines European public assessment report (EPAR): Xalkori, crizotinib, D...
Addendum to the Guideline on clinical development of vaccines to address clinica...
Clinical evaluation of new vaccines - Scientific guideline
Clinical Trial Information System (CTIS) evaluation timelines
Human medicines European public assessment report (EPAR): Voydeya, Danicopan, Da...
Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, D...
Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,...
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...
Human medicines European public assessment report (EPAR): Fasenra, benralizumab,...
Human medicines European public assessment report (EPAR): Somavert, pegvisomant,...
Herbal medicinal product: Prunus avium peduncle, Prunus avium L.,Prunus cerasus ...
Herbal medicinal product: Tribuli terrestris herba, Tribulus terrestris L., D: D...
Herbal medicinal product: Pilosellae herba cum radice, Hieracium pilosella L., F...
SAN FRANCISCO, U.S. and SUZHOU, China, February 17, 2025 — Innovent Biologics, I...